Annuncio pubblicitario
Italia markets closed

  • FTSE MIB

    33.629,21
    -107,19 (-0,32%)
     

  • Dow Jones

    38.675,68
    +450,02 (+1,18%)
     

  • Nasdaq

    16.156,33
    +315,37 (+1,99%)
     

  • Nikkei 225

    38.236,07
    -37,98 (-0,10%)
     

  • Petrolio

    77,99
    -0,96 (-1,22%)
     

  • Bitcoin EUR

    59.181,27
    +770,15 (+1,32%)
     

  • CMC Crypto 200

    1.328,92
    +51,94 (+4,07%)
     

  • Oro

    2.310,10
    +0,50 (+0,02%)
     

  • EUR/USD

    1,0765
    +0,0038 (+0,36%)
     

  • S&P 500

    5.127,79
    +63,59 (+1,26%)
     

  • HANG SENG

    18.475,92
    +268,79 (+1,48%)
     

  • Euro Stoxx 50

    4.921,48
    +30,87 (+0,63%)
     

  • EUR/GBP

    0,8577
    +0,0023 (+0,27%)
     

  • EUR/CHF

    0,9735
    -0,0024 (-0,25%)
     

  • EUR/CAD

    1,4726
    +0,0064 (+0,44%)
     

Fate Therapeutics to Present at Upcoming September Investor Conferences

Fate Therapeutics, Inc.
·2 minuto per la lettura
Fate Therapeutics, Inc.
Fate Therapeutics, Inc.

SAN DIEGO, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that the Company will participate in the following upcoming investor conferences:

Citi’s 18th Annual BioPharma Conference on Thursday, September 7, 2023 in Boston, Massachusetts

  • Hosting 1x1 investor meetings only

Wells Fargo 2023 Healthcare Conference on Friday, September 8, 2023 at 9:30 AM ET in Boston, Massachusetts

ANNUNCIO PUBBLICITARIO

  • Participating in a fireside chat and hosting 1x1 investor meetings

A live webcast, if recorded, of each presentation can be accessed under “Events & Presentations” in the Investors section of the Company’s website at www.fatetherapeutics.com. The archived webcast will be available on the Company’s website shortly after the event.

About Fate Therapeutics, Inc.

Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s effector cell pipeline includes multiplexed-engineered, iPSC-derived natural killer (NK) cell and T-cell product candidates, which incorporate novel synthetic controls of cell function, such as chimeric antigen receptors (CARs) to target tumor-associated antigens, and are intended to deliver multiple mechanisms of therapeutic importance to patients including in combination with well-established cancer therapies. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.

Contact:
Christina Tartaglia
Stern Investor Relations, Inc.
212.362.1200
christina.tartaglia@sternir.com